SpiraBrush CX®

Physicians have turned to Pathology, Inc.’s SpiraBrush CX^® testing over 30,000 times.

SpiraBrush CX, the FDA-cleared* alternative to punch forceps for cervical biopsy specimens*

Pathology, Inc.’s outstanding cervical biopsy testing begins with the SpiraBrush CX. The SpiraBrush CX biopsy brush is an FDA-cleared cervical biopsy device designed to be used in most cervical biopsy procedures in place of the traditional punch or forceps cervical biopsy instrument. The unique, stiff-bristled, spiral-shaped design of the SpiraBrush CX makes possible the removal of a full layer of squamous epithelium^1,2 of the cervix with minimal trauma to the patient and less bleeding. Diagnostic accuracy of SpiraBrush CX has been evaluated using LEEP¹ as the gold standard with the resulting correlation being compared to that of the punch biopsy.

Pathology, Inc.—experience and excellence in SpiraBrush CX^® Testing

• Pathology, Inc. was the first to market and has the most experience of any lab in the country interpreting/analyzing SpiraBrush CX biopsies
• SpiraBrush CX biopsies require analysis by pathologists specially trained in interpreting SpiraBrush CX specimens; Pathology, Inc. has the most experienced pathologists interpreting SpiraBrush CX results
• Pathology, Inc. provides rapid 24 - 48 hour turnaround time on biopsy results and offers convenient consultative services

Considerate For Your Patients:

• Less pain
• Less bleeding
• Less anxiety

Convenient For You:

• Practical, easy-to-use
• One-time use, disposable
• Full thickness transepithelial biopsy^1,2
• Reduces need for forceps biopsy
• Reduces need for Monsels, silver nitrate
• Reduces need to autoclave and re-sharpen forceps

Clinical Performance:

• Diagnostic accuracy evaluated using LEEP¹ as the gold standard
• Result correlation compared to punch biopsy¹
  • Sensitivity
    • SpiraBrush -- 89%
    • Punch Biopsy -- 90.2%

Indications

• Obtaining a biopsy of suspicious areas or visible exocervical lesions for the purpose of obtaining a tissue diapnosis during colposcopic examination
• Tissue samples should be evaluated by a pathologist familiar with the evaluation of SpiraBrush CX^® cervical biopsies

Contradictions

• Patient currently on anticoagulant therapy
• Patients with known bleeding disorders
• Not a substitute for endocervical curettage during colposcopy
• Only samples epithelium, thus the biopsy should not be used alone if colposcopic findings are highly suspicious for invasive disease
• Has not been studied in pregnant patients; benefits in pregnant women must be weighed against any possible risks
• Evaluation of Pap Test interpretation of atypical glandular cells

More Related Information

• SpiraBrush CX^® PACKAGE INSERT Cervical Biopsy Device